Mounjaro, a weekly injection, targets GIP and GLP-1 hormones to enhance insulin release and appetite regulation, aiding ...

Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's ...

JM Financial is bullish on Mounjaro's success in India, citing its price advantage, higher efficiency and the country's large ...

Eli Lilly CEO David Ricks reveals that developing a new drug costs around $4 billion before marketing. In an exclusive ...

GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...

Mounjaro is a very big opportunity, given that a significant number of people have diabetes in India, says the CEO ...

Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, ...

Eli Lilly's CEO, David Ricks, reveals potential plans to manufacture the weight-loss drug Mounjaro in India as part of their global expansion.

Mounjaro (Tirzepatide), a groundbreaking GLP-1 receptor agonist targeting GIP receptors, is now available in India for ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ...